Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Editorial

The Imaging of Lung Cancer: A Complete Vision

Author(s): Luigi Mansi and Laura Evangelista

Volume 13, Issue 3, 2020

Page: [165 - 165] Pages: 1

DOI: 10.2174/187447101303201029121009

Next »
[1]
American Cancer Society Cancer facts and figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (Accessed 15 July, 2019)
[2]
Fakiris, A.J.; McGarry, R.C.; Yiannoutsos, C.T. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 677-682.
[3]
Hirsch, F.R.; Scagliotti, G.V.; Mulshine, J.L.; Kwon, R.; Curran, W.J., Jr; Wu, Y.L. Lung cancer: current therapies and new targeted treatments. Lancet, 2017, 389, 299-311.
[4]
Bütof Esther, R.; Troost, G.C. The role of functional imaging in lung cancer. Clin. Transl. Imaging, 2018, 6, 441-447.
[5]
Panunzio, A.; Sartori, P. Lung Cancer and Radiological Imaging. Curr. Radiopharm., 2019, 13, 238-242.
[6]
Farsad, M. FDG PET/CT in staging of lung cancer. Curr. Radiopharm., 2019, 13, 195-203.
[7]
Castello, A.; Rossi, S.; Lopci, E. 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of art. Curr. Radiopharm., 2019, 13, 228-237.
[8]
Evangelista, L.; Sepulcri, M.; Pasello, G. PET/CT and The Response to Immunotherapy In Lung Cancer. Curr. Radiopharm., 2019, 13, 177-184.
[9]
Filice, A.; Casali, M.; Ciammella, P.; Galaverni, M.; Fioroni, F.; Iotti, C.; Versari, A. Radiotherapy planning and Molecular Imaging in Lung Cancer. Curr. Radiopharm., 2019, 13, 204-217.
[10]
Crivellari, C.; Guerra, L. Respiratory Gating and the performance of PET/CT in pulmonary lesions. Curr. Radiopharm., 2019, 13, 218-227.
[11]
Spadafora, M.; Evangelista, L.; Fiordoro, S.; Porcaro, F.; Sicignano, M.; Mansi, L. The multicenter ITALIAN trial assess the performance of FDG-PET/CT related to pre-test cancer risk in patients with solitary pulmonary nodules and introduces a segmental thoracic diagnostic strategy. Curr. Radiopharm., 2019, 13, 243-248.
[12]
Telo, S.; Calderoni, L.; Vichi, S.; Zagni, F.; Castellucci, P.; Fanti, S. Alternative and New Radiopharmaceutical Agents for Lung Cancer. Curr. Radiopharm., 2019, 13, 185-194.
[13]
Briganti, V.; Cuccurullo, V.; Berti, V.; Di Stasio, G.D.; Linguanti, F.; Mungai, F.; Mansi, L. 99mTc-EDDA/HYNIC-TOC is a new opportunity in Neuroendocrine Tumors of the Lung (and in other malignant and benign pulmonary diseases). Curr. Radiopharm., 2019, 13, 166-176.

© 2024 Bentham Science Publishers | Privacy Policy